18+ · Research Use Only · Not for Human Consumption

Primara LabsPrimara Labs
60-day guarantee

Changelog

What changed, and when.

The most recent change to primaralabs.com was on 23 September 2026. Each entry below is dated and links to what changed, so a reader can see how current any page is.

Updated 23 September 2026

8 entries

Newest first

  1. Answers to the questions buyers ask

    48 answer pages, each opening with a dated direct answer and citing the source of every figure: approval status by compound, trial results and side effects, what lab tests show and cost, ordering, price and delivery. 5 Taglish versions await review before they are indexed.

  2. Supplier checklist and delivery checker

    Two new tools: 10 checks to apply to any peptide seller in the Philippines, with how Primara answers each, and a checker that gives the delivery window, courier, fee and cutoff for any covered city or province.

  3. Fact sheet, press kit and entity data

    The facts about Primara Labs in one place, each generated from the file that holds it, with a press kit and the same facts as JSON. Every structured-data reference to the business now points at one organization record.

  4. Machine-readable pages

    Every public page is also available as markdown at its path plus .md, the full text of product, research and answer pages is in one file at /llms-full.txt, and the sitemap is split by section with real last-changed dates.

  5. Identity and status corrections

    Molecular formulas in the catalogue checked against PubChem and corrected or withheld; the TB-500 and CJC-1295 specifications read "Confirming with supplier" until the supplier confirms the molecule. The tirzepatide and semaglutide descriptions now separate the US-approved medicines from the research vial. The FDA Philippines advisories list grew to 8.

  6. The Research Desk

    9 free datasets and two tools on the compounds in the catalogue: an Evidence Map, a Trial Explorer, a Regulatory Status Tracker, a COA Reader and a Lab Test Planner, every figure linked to its primary source and dated, each dataset downloadable as JSON and CSV.

  7. Product pages rebuilt

    All 17 product pages now carry the benefits studied with their evidence level, the side effects reported, how the compound works, what the research shows, a specification sourced to PubChem, handling, batch reports and regulatory status.

  8. First batch report published

    Retatrutide batch RETA-4728-A is Janoshik-tested for bacterial endotoxin: 6.066 EU per vial, analysed 21 September 2026 (task 234146, key H2KI86I8GWB4). This report covers bacterial endotoxin only. It does not establish identity or purity.